Breaking News

Tonix Pharma Names Clinical Development and RA SVP

April 1, 2014

Kellerman to oversee strategy and execution of clinical programs

Donald J. Kellerman, Pharm.D. has been appointed senior vice president of Clinical Development and Regulatory Affairs at Tonix Pharmaceuticals. Dr. Kellerman will be responsible for overseeing strategy and execution of the company’s clinical programs.
Dr. Kellerman has more than 30 years of experience in pharmaceutical development, spanning several therapeutic areas including central nervous system, respiratory, allergy, ophthalmology and cardiovascular. Dr. Kellerman previously served as senior vice president, Clinical Development and Medical Affairs at MAP Pharmaceuticals, Inc. (acquired by Allergan, Inc.), where he managed the development of MAP0004 for the treatment of migraine. Dr. Kellerman also held positions at Inspire Pharmaceuticals, Inc. (acquired by Merck), Glaxo Wellcome plc, Sepracor, Inc. (acquired by Dainippon Sumitomo Pharma Co.), Ciba-Geigy Corp., and E.R. Squibb and Sons, Inc.
"We welcome Don Kellerman to Tonix's executive management team as we bring our headache program into the clinic later this year," said Seth Lederman, MD, president and chief executive officer of Tonix. "His recent and successful experience shepherding a novel formulation of a decades-old agent for migraine through a registration program and a New Drug Application (NDA) submission is reflective of our business approach and will be of great value to Tonix."

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016